CVS Caremark relaunches website for PBM members
WOONSOCKET, R.I. — In an effort to further enhance the online experience for its pharmacy benefit management members, CVS Caremark announced it has relaunched Caremark.com.
The updated website, which boasts improved navigation and easy-to-understand language, is enhanced to provide PBM members a comprehensive destination site that allows them to easily manage their prescription benefits.
Caremark.com also sports such new features as:
My Dashboard: A personalized dashboard featuring a dynamic, tailored list of action items for the member, including placing orders, identifying savings opportunities, updating his or her profile and viewing his or her medication history;
Medication History: Members can view their past and current prescriptions in one place; and
Easy Refills: Faster and easier ways to place orders, manage alerts and use mobile apps.
CVS Caremark members with Caremark.com accounts do not need to re-register on the new site, the company noted.
"The relaunch of Caremark.com is another example of our commitment to finding innovative and effective ways to engage our PBM members to help them make quality healthcare decisions," said Tim Kurth, VP e-business at CVS Caremark. "The refreshed site design, use of member-focused language and a variety of new features make it even easier for our members to manage their prescriptions online, stay adherent to their medications and identify opportunities for increased savings."
Armada introduces ReachRx OTM
FLORHAM PARK, N.J. — Armada Health Care has launched a new Web-based specialty pharmacy therapy management system designed to allow pharmacies to optimize drug utilization and clinical outcomes while providing enhanced patient care, Armada said Monday.
The company announced the launch of ReachRx OTM, which includes features such as patient support protocols, side effects management, therapy discontinuation surveys and patient outcomes reporting.
Armada said the system’s reporting capabilities would assist pharmacies to optimize fiscal management, meet payer requirements and access biotech manufacturer programs requiring patient interventions and reporting.
Tradjenta approved as Type 2 diabetes treatment
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for Type 2 diabetes, the agency said Monday.
The FDA announced the approval of Tradjenta (linagliptin), made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.
“This approval provides another treatment option for the millions of Americans with Type 2 diabetes,” FDA Division of Metabolism and Endocrinology Products director Mary Parks said. “It is effective when used alone or when added to existing treatment regimens.”